Amrix

AMRIX — cyclobenzaprine hydrochloride capsule, extended release
STAT RX USA LLC

AMRIX® (Cyclobenzaprine Hydrochloride Extended-Release Capsules) is a skeletal muscle relaxant which relieves muscle spasm of local origin without interfering with muscle function. The active ingredient in AMRIX extended-release capsules is cyclobenzaprine hydrochloride, USP. Cyclobenzaprine hydrochloride (HCl) is a white, crystalline tricyclic amine salt with the empirical formula C20 H21 N•HCl and a molecular weight of 311.9. It has a melting point of 217°C, and a pKa of 8.47 at 25°C. It is freely soluble in water and alcohol, sparingly soluble in isopropanol, and insoluble in hydrocarbon solvents. If aqueous solutions are made alkaline, the free base separates. Cyclobenzaprine HCl is designated chemically as 3-(5H -dibenzo[a,d ] cyclohepten-5-ylidene)-N,N -dimethyl-1-propanamine hydrochloride, and has the following structural formula:

image of chemical structure

AMRIX extended-release capsules for oral administration are supplied in 15 and 30 mg strengths. AMRIX capsules contain the following inactive ingredients: diethyl phthalate NF, ethylcellulose NF (Ethocel Standard 10 Premium), gelatin, Opadry® Clear YS-1-7006, sugar spheres NF (20-25 mesh), and titanium dioxide. AMRIX 15 mg capsules also contain D&C yellow #10, FD&C green #3, and FD&C red #40. AMRIX 30 mg capsules also contain FD&C blue #1, FD&C blue #2, FD&C red #40, and FD&C yellow #6.

CLINICAL PHARMACOLOGY

Cyclobenzaprine relieves skeletal muscle spasm of local origin without interfering with muscle function. Cyclobenzaprine has not been shown to be effective in muscle spasm due to central nervous system disease. In animal models, cyclobenzaprine reduced or abolished skeletal muscle hyperactivity. Animal studies indicate that cyclobenzaprine does not act at the neuromuscular junction or directly on skeletal muscle. Such studies show that cyclobenzaprine acts primarily within the central nervous system at the brain stem as opposed to the spinal cord level, although an overlapping action on the latter may contribute to its overall skeletal muscle relaxant activity. Evidence suggests that the net effect of cyclobenzaprine is a reduction of tonic somatic motor activity, influencing both gamma (γ) and alpha (α) motor systems. Pharmacological studies in animals demonstrated a similarity between the effects of cyclobenzaprine and the structurally related tricyclic antidepressants, including reserpine antagonism, norepinephrine potentiation, potent peripheral and central anticholinergic effects, and sedation. Cyclobenzaprine caused slight to moderate increase in heart rate in animals.

PharmacokineticsAbsorption

In a single-dose study comprised of healthy adult males (n=15), the dose adjusted ratios of the arithmetic means of AUC0-168 and AUC0-∞ indicated that exposure of the AMRIX 30 mg was about 16% and 10% higher than that of AMRIX 15 mg, respectively. The dose-adjusted ratios of the arithmetic means of Cmax indicated that the peak plasma concentration of AMRIX 30 mg was about 20% higher than that of AMRIX 15 mg. The half-lives and time to peak plasma cyclobenzaprine concentration were similar for both AMRIX 15 mg and 30 mg. These data are summarized below.

Table 1: Summary of Pharmacokinetic Parameters in Healthy Adult Subjects
ParameterMean ± SDAMRIX 15 mg(N=15)AMRIX 30 mg(N=14)
AUC0-168 (ng•hr/mL)318.3 ± 114.7736.6 ± 259.4
AUC0-∞ (ng•hr/mL)354.1 ± 119.8779.9 ± 277.6
Cmax (ng/mL)8.3 ± 2.219.9 ± 5.9
Tmax (hrs)8.1 ± 2.97.1 ± 1.6
t1/2 (hrs)33.4 ± 10.332.0 ± 10.1

SD = standard deviation

A food effect study conducted in healthy adult subjects (n=15) utilizing a single dose of AMRIX 30 mg demonstrated a statistically significant increase in bioavailability when AMRIX 30 mg was given with food relative to the fasted state. There was a 35% increase in peak plasma cyclobenzaprine concentration (Cmax ) and a 20% increase in exposure (AUC0-168 and AUC0-∞ ) in the presence of food. No effect, however, was noted in Tlag , Tmax , or the shape of the mean plasma cyclobenzaprine concentration versus time profile. Cyclobenzaprine in plasma was first detectable in both the fed and fasted states at 1.5 hours.

In a multiple-dose study utilizing AMRIX 30 mg administered once daily for 7 days in a group of healthy adult volunteers (n=35) a 2.5-fold accumulation of plasma cyclobenzaprine levels was noted at steady-state.

Metabolism and Elimination

Cyclobenzaprine is extensively metabolized and is excreted primarily as glucuronides via the kidney. Cytochromes P-450 3A4, 1A2, and, to a lesser extent, 2D6, mediate N-demethylation, one of the oxidative pathways for cyclobenzaprine. Cyclobenzaprine has an elimination half-life of 32 hours (range 8-37 hours; n=18); plasma clearance is 0.7 L/min following single dose administration of AMRIX.

Special PopulationsElderly

Although there were no notable differences in Cmax or Tmax , cyclobenzaprine plasma AUC is increased by 40% and the plasma half-life of cyclobenzaprine is prolonged in elderly subjects greater than 65 years of age (50 hours) after dosing with AMRIX compared to younger subjects (32 hours). Pharmacokinetic characteristics of cyclobenzaprine following multiple-dose administration of AMRIX in the elderly were not evaluated.

Table 2: Summary of Pharmacokinetic Parameters of AMRIX 30 mg Extended-Release Capsules, By Age Group
Parameter Mean ± SD AMRIX 30 mg QD
18 to 45 years(N=18) 65 to 75 years(N=17)
AUC0-168 (ng•hr/mL)715.1 ± 264.2945.9 ± 255.2
AUC0-∞ (ng•hr/mL)751.2 ± 271.51055.2 ± 301.9
Cmax (ng/mL)*19.2 ± 5.619.2 ± 5.1
Tmax (hrs)*6.8 ± 1.98.5 ± 2.3
t1/2 (hrs)32.4 ± 8.149.0 ± 8.3

* Measured over the entire 24 hour period

SD= standard deviation

Hepatic Impairment

In a pharmacokinetic study of immediate-release cyclobenzaprine in 16 subjects with hepatic impairment (15 mild, 1 moderate per Child-Pugh score), both AUC and Cmax were approximately double the values seen in the healthy control group. The pharmacokinetics of cyclobenzaprine in subjects with severe hepatic impairment is not known.

CLINICAL STUDIES

Efficacy was assessed in two double-blind, parallel-group, placebo-controlled studies of identical design of AMRIX 15 mg and 30 mg taken once daily in patients with muscle spasms associated with acute painful musculoskeletal conditions.

There were significant differences in the primary efficacy analysis, the patient’s rating of medication helpfulness, between the AMRIX 15 mg group and the placebo group at Days 4 and 14 in one study and between the AMRIX 30 mg group and the placebo group at Day 4 in the second study.

Table 3: Subject’s Rating of Medication Helpfulness — Study 1105
Day 4 Day 14
Number of Subjects (%) Number of Subjects (%)
Placebo(N = 64) AMRIX 30 mg(N = 64) Placebo(N = 64) AMRIX 30 mg(N = 64)
Excellent 1 (1.6%) 3 (4.7%) 12 (18.8%) 15 (23.4%)
Very Good 5 (7.8%) 13 (20.3%) 9 (14.1%) 19 (29.7%)
Good 15 (23.4%) 22 (34.4%) 10 (15.6%) 15 (23.4%)
Fair 24 (37.5%) 20 (31.3%) 16 (25.0%) 10 (15.6%)
Poor 10 (15.6%) 5 (7.8%) 9 (14.1%) 4 (6.3%)
Missing 9 (14.1%) 1 (1.6%) 8 (12.5%) 1 (1.6%)
Table 4: Subject’s Rating of Medication Helpfulness — Study 1106
Day 4 Day 14
Number of Subjects (%) Number of Subjects (%)
Placebo(N = 64) AMRIX 15 mg(N = 63) Placebo(N = 64) AMRIX 15 mg(N = 63)
Excellent 1 (1.6%) 2 (3.2%) 10 (15.6%) 13 (20.6%)
Very Good 10 (15.6%) 12 (19.0%) 12 (18.8%) 21 (33.3%)
Good 14 (21.9%) 21 (33.3%) 13 (20.3%) 9 (14.3%)
Fair 16 (25.0%) 17 (27.0%) 14 (21.9%) 10 (15.9%)
Poor 19 (29.7%) 6 (9.5%) 12 (18.8%) 5 (7.9%)
Missing 4 (6.3%) 5 (17.9%) 3 (4.7%) 5 (7.9%)

In addition, one of the two studies demonstrated significant differences between the AMRIX 30 mg group and the placebo group in terms of patient-rated relief from local pain due to muscle spasm at Day 4 and Day 8, in subject-rated restriction of movement at Day 4 and Day 8, and in patient-rated global impression of change at Day 4, Day 8, and Day 14.

There were no significant treatment differences between the AMRIX treatment groups and the placebo group in physician’s global assessment, in subject-rated restriction in activities of daily living, or quality of night-time sleep.

Page 1 of 3 1 2 3

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2024. All Rights Reserved.